The gray market
When the tan reaches your mouth: the side effect no mirror warned you about
In this piece
There are places a tan was never meant to follow you. The inside of your mouth is one of them.
Yet brown patches on the gums and inner cheeks are now part of the published Melanotan II record. Not a court-of-public-opinion anecdote: a dental case report with examination photographs, a drug history, and follow-up after the patient stopped using the product.
This matters for the person who notices an unfamiliar dark patch and gets two opposite answers from the internet: it’s just the peptide, or it’s definitely cancer. Neither answer fits the evidence. A drug-associated pigment change is possible; a specific pigment change still has to be assessed.
The mirror did not invent the signal
A 2026 report in Life (PMC12942211; DOI: 10.3390/life16020265) described a 42-year-old man attending a routine dental visit after taking Melanotan II to deepen his tan. The dentist found almost symmetrical brown pigmentation on the attached gingiva in both jaws, together with irregular pigmented areas on the lining of both cheeks.
Gingiva is the medical name for gums. Buccal mucosa is the lining of the cheeks. Those were the sites in this case. The patient’s lips, tongue and palate showed no pigmentation at that examination.
That is worth stating precisely, because a search for “Melanotan lips” can otherwise manufacture a documented symptom the paper did not report. The relevant clinical sign here was pigmentation inside the mouth, not a universal list of what every Melanotan user should expect.
The patient reported both tobacco use and regular sunbed use. Some gum pigmentation had also been noted at an earlier dental visit two years before the reported Melanotan II exposure; the distribution and intensity had since changed. Those details make his history less tidy than a slogan. They do not erase the documented association. They show why an accurate medical history is part of the evidence rather than a conversational extra.
One lesion, two different questions
The drug’s cosmetic proposition concerns skin. Skin pigment cells are not, however, the only melanocytes a person has. Melanocytes also occur in oral mucosal tissue. The case authors describe a plausible mechanism in which MC1R stimulation on oral melanocytes increases melanin production and transfer to neighbouring cells — consistent with the non-selective, whole-body signal the molecule delivers.
That mechanistic explanation is a way to understand an observation, not proof of a particular patient’s diagnosis. There are other causes of brown, blue-grey or black patches in the mouth. A clinical review of pigmented oral lesions lists physiological pigmentation, post-inflammatory pigmentation, smoker’s melanosis, an amalgam tattoo, benign pigmented lesions and malignant conditions among the possibilities. These can look similar even though their clinical significance is very different.
So the useful split is:
- Could the product be involved? Yes, that is in the published case literature.
- Does appearance prove the product is responsible? No, not from a photograph or from the fact that your skin became darker at the same time.
The second question is the clinician’s job. It may involve a dental and medical history, examination, and — when indicated — a biopsy. This article cannot turn the appearance of a particular patch into an answer for you.
The colour can outlast the container
In the new case, after the man stopped the injections, cheek pigmentation had almost disappeared at the one-month follow-up. At three months the gum pigmentation was visibly reduced but had not completely resolved. The report’s more detailed clinical table records cheek improvement at 28 days and some remaining cheek macules at three months: improvement was real, but not the same for every site.
The article credited above supplies those observations. It does not establish a typical duration or an “expected outcome” for someone else. Nor can it separate every contribution from pre-existing gum pigment, tobacco use or sunbeds. What it establishes is more modest: a person’s oral appearance can remain changed beyond the cosmetic course, and dental follow-up can document it.
This should not be recast as a waiting period. A new pigmented lesion may need an examination while it is present, not after a self-imposed countdown designed to see whether it fades.
That is different from the familiar mole-darkening problem, but the diagnostic caution is the same: the drug changes the background against which a concerning change is noticed.
The separate melanoma report deserves neither silence nor a shortcut
There is a second, more alarming case in the mouth-focused literature. A peer-reviewed report indexed in 2025 (DOI: 10.1016/j.ijom.2025.03.014) described a 22-year-old woman who used a Melanotan II nasal spray and subsequently developed a mass in the upper jaw. Histological examination diagnosed mucosal malignant melanoma; the abstract reports surgical removal and ongoing immunotherapy.
That case is not made up, and it is not proof of causation. A case report can put a diagnosis and an exposure in the same clinical record; it cannot calculate how often the drug causes that diagnosis. The two issues should not be blended: diffuse brown pigmentation is not the same finding as a malignant oral tumour, and the presence of one in the literature does not convert the other into a prediction.
It also does not exonerate a nasal route. Changing the container removes the needle, not the compound or its product-quality questions. An oral case associated with a spray does not establish that injection is safer; this article’s pigmentation case involved injections. The useful comparison is not “which format is safe” but what each report actually records.
Bring the mouth and the history
A new dark patch, a lump, an ulcer that will not heal or another unexplained mouth change warrants a dental or medical assessment. It does not have to hurt before it deserves that attention.
Disclose the product by name, when you used it, alongside any sunbed, tobacco, medicine and health history, and when you first noticed the change. “Tanning supplement” is too vague for someone trying to interpret a pigment change. Bring an earlier photograph when available; use the current one as a record for the clinician, not as your diagnosis.
The NHS mouth-symptom guidance specifically advises a doctor or dentist review for an ulcer lasting more than three weeks, a mouth or lip lump, a red or white patch, or persistent mouth pain. Those symptoms have many causes and do not automatically mean cancer. Rapid growth, spontaneous bleeding, ulceration or a firm/raised new lesion likewise belong in professional hands, not a symptom-comparison thread.
The simplest response is not panic. It is to have what the mirror found examined, with the whole history on the record.
Sources consulted
- Bonchev A (2026). Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. Life, 16(2), 265. Brown pigmentation of the attached gingiva in both jaws, plus irregular, bilateral buccal-mucosa pigmentation; some pigment had been documented before the exposure. One-month and three-month clinical follow-up; remaining pigmentation varied by site. The report explicitly frames its mechanism and limitations as those of a single observed case.
- Wolk R, Massi D, Trochesset D (2025). Pigmented Lesions of the Oral Mucosa: Clinical Presentation, Histology, and Recommendations for Management. American Journal of Clinical Dermatology. It includes post-inflammatory pigmentation among a broad differential of physiologic, reactive, exogenous, benign-neoplastic and malignant causes. Careful evaluation, and biopsy when indicated, is relevant because appearance alone may not distinguish them.
- Alsabbagh ASM et al. (2025). Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?. International Journal of Oral and Maxillofacial Surgery, 54(9):806–808. Case report of a diagnosed oral mucosal melanoma in a young woman after nasal-spray use. It reports the case and the need for awareness, not a causal rate or proof that Melanotan II caused that tumour.
- NHS. Symptoms of mouth cancer. Public-facing escalation guidance for mouth ulcers, lumps, persistent pain and red/white patches; stresses both medical assessment and that common symptoms usually have other explanations.
Common questions
Can Melanotan II darken your gums or the inside of your cheeks?
Oral pigmentation has been described in published case reports. A 2026 report documented new or darker brown patches on a man's gums and the insides of his cheeks while he was using injected Melanotan II. His case had a three-month dental follow-up. It is still a case report, not an estimate of how often this happens.
Does Melanotan II darken lips?
The 2026 follow-up case is not evidence that it does: the man's lips, tongue and palate showed no pigmentation at the documented examination. A new lip pigment still deserves a dental or medical assessment. Oral pigmentation has several causes that cannot be distinguished by appearance alone.
Does a dark patch in your mouth mean Melanotan II caused cancer?
No. Oral pigmentation is not a diagnosis of melanoma. A separate 2025 case report described an oral mucosal melanoma in a young woman after a Melanotan II nasal spray, but one case cannot show that the product caused the tumour. A changing or unexplained patch, lump or ulcer needs a clinician, not a reassuring label from a mirror.
Do Melanotan II mouth patches go away?
In the 2026 case, cheek pigmentation started improving within a month after the product was stopped, while gum pigmentation was reduced but still present at three months. That timeline describes one observed person. It is not a guaranteed recovery time or a reason to wait rather than have a new lesion examined.